bulk retatrutide Research Supply Retatrutide 20mg Peptides | 99%

The Phase 2/3 LIFT-AD trial (NCT04488419), evaluating once-daily subcutaneous fosgonimeton 40 mg versus placebo in 312 participants with mild-to-moderate Alzheimers disease over 26 weeks, failed its primary endpoint (Global Statistical Test composite of ADAS-Cog11 and ADCS-ADL23) and its key secondary endpoints when results were announced in September 2024

Research Applications This peptide is supplied for in-vitro laboratory research only

Self-insured plans offered by larger employers and administered by Blue Cross may be influenced by the policy change but have more flexibility since they pay their own claims

Sarah was great at helping purchase this

Unger JW, Moss AM, Livingston JN